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Successful clinical trials are important for
all of us, but they can be extremely com-
plicated to design and run, so work must
be done to consider what commonly goes
wrong and how these issues can be
addressed. Gelinas et al suggest an ethical
argument for institutional prioritisation of
clinical trials conducted among limited
populations. This is to ensure successful
recruitment and prevent competing trials
rendering each other irrelevant through
lack of statistical power. But they overlook
the fact that effective prioritisation
already occurs, and their suggestion pro-
duces yet another hurdle for researchers
to overcome.
Their argument hinges around the
claim that allocation of participants to
trials represents an inevitable rationing
scenario and, like all rationing scenarios,
the best methods should be used for
objectively determining how limited
resources (participants) are distributed to
achieve the end goal (successful clinical
trials).1 Although they acknowledge that
both individuals and clinicians may have
preferences as to which trial a patient par-
ticipates in, trial interventions are by def-
inition experimental, and therefore
choosing between trials is not really analo-
gous to choosing between alternative clin-
ical interventions. Here it seems that
although clinical instinct is important
when determining treatment options, a
clinical trial is a specific attempt to create
systematic justified knowledge and thus
individual patient/clinician autonomy is
not particularly relevant. They also argue
that neither randomisation (determining
which trials should be able to recruit first
by flipping a coin) nor the prioritisation
of the wealthiest trials represents sound
ways to determine which trials should be
prioritised. These are important and valu-
able arguments.
Gelinas et al also seem mostly correct
in arguing that a fundamental tenet in
research ethics is justified by risk–benefit
ratio. If a trial does not recruit adequately,
there is no overall social benefit to
balance the risks taken by participants
already recruited on the trial. However,
they are too quick to state that benefit for
a small number of participants can never
justify a trial. They seem overly enam-
oured with the more traditional ‘block-
buster’ model of drug development
without fully appreciating that drugs or
treatments may have very different effects
in small and subtly different populations.
Indeed, a number of fruitful research
avenues (such as pharmacogenetics)
include combing through data from
apparently ‘failed’ trials to work out if
drugs or treatments might be successful in
subpopulations.2 A second pertinent issue
is that failed trials may produce valuable
methodological lessons that will benefit
the trials community.3 Gelinas et al are
therefore not correct when they argue
that underpowered or under-recruited
trials never produce benefits to offset risks
to participants.
The paper makes the suggestion that
trials should be prioritised on an institu-
tional basis by either limiting the number
of trials that can be open for recruitment
at any one time or creating a rank order
of trials where those at the top of the list
get first access to the patients who are
only told about subsequent trials if they
decline to participate in the first ranked
trial. The authors acknowledge that the
issue of how to rank trials is not straight-
forward, and indeed almost immediately
seem to contradict an earlier part of their
argument by stating that sometimes it may
be ethically justified to give potential par-
ticipants the choice between a high risk,
but potentially high reward trial, and a
low risk but low reward trial. However, to
be charitable, this is within the context of
giving two trials an equal rank when there
are multiple possible trials.
They then argue that so long as institu-
tions use a transparent and consistent
system to prioritise trials such a system
would be fair to participants, investigators
and funders. For participants, although
patient–participant involvement (PPI) is
an important and increasing priority in
trial design,4 there is no apparent positive
moral right to have all possible trials
made available to every patient. Indeed,
sometimes limiting trial options may be
ethically preferable both to help avoid
therapeutic misconception and avoid the
possibility of very sick patients or their
relatives blaming themselves for choosing
the wrong trial. For investigators or their
funders, while they are perhaps most
likely to complain that an institutional
allocation system is unfair if it does not
prioritise their particular study, it is not
beyond the realms of administrative possi-
bility to coordinate efforts between
funders, investigators and institutions at
the earlier planning stages of projects to
ensure that a fair and workable solution is
produced.
Although it is no doubt helpful to have
arguments such as these rehearsed,
Gelinas et al seem to overlook the fact
that trial prioritisation already occurs.
Granted individual institutions seldom
have the systems that the authors advo-
cate, and it is no doubt frustrating for
investigators based at small institutions
with limited participant populations, but
large drug trials are almost always multi-
centre if not multinational and are sub-
stantially ranked and prioritised within
companies, funding agencies or clinical
trial units. Such prioritisation already pro-
ceeds more or less as described by the
authors, relying initially on peer review,
then taking into account social (or
market) benefits, and sometimes even
undergoing international coordination
such as seen during the recent Ebola out-
break.5 Furthermore, clinicians frequently
communicate with each other, and while
the problem of incentives should never be
ignored, the clinical research community
is a place of rigorous debate with clini-
cians often coordinating efforts infor-
mally. Even research ethics committees
consider the issue of adequate recruit-
ment, asking investigators how big recruit-
ment pools are and how many other
studies are currently recruiting from the
same pool prior to giving a favourable
opinion. Although it may never be pos-
sible to entirely eradicate the problem of
trial under-recruitment, and certainly
local or regional studies are most likely to
run into problems, the issue of under-
recruitment is already well appreciated
within the trial community. Proposing
additional prioritisation or ranking
schemes at an institutional level will
simply produce yet another level of bur-
eaucracy in an already arguably overlegis-
lated area of research.
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